Drug that targets scar-like tissue in tumours shows promise for aggressive pancreatic cancer

Findings from the Garvan Institute of Medical Research reveal a new Australian drug that targets scar-like 'fibrotic' tissue within tumours shows promise for treating pancreatic ductal adenocarcinoma, one of the most aggressive forms of pancreatic cancer with a five-year survival rate of less than 10%. The research in mouse models showed that when given in combination with chemotherapy, the drug PXS-5505 increased survival time by more than 35%, compared to chemotherapy treatment alone.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news